MedAlliance Gains CE Mark Approval for Coronary SELUTION SLR™ ...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
NYON, Switzerland, June 30, 2020 /PRNewswire-AsiaNet/ -- MedAlliance has announced the award of its second CE Mark: SELUTION SLR™ 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease. This includes indications for both de-novo lesions as well as in-stent...
Authors: LATEST ASIANET NEWS RELEASES